Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tayeb Hussain

Podiatrist Evanston, IL Doctor of Podiatric Medicine

NPI 1487688925 CMS profile 690584

2500 Ridge Ave, Suite 110, Evanston, IL 60201

Open in the dashboard

General payments

$15,115

451 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tayeb Hussain of Evanston, IL is reported in the CMS Open Payments database as having received $15,115 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,771 51
2024 General $1,941 49
2023 General $1,752 60
2022 General $2,951 58
2021 General $2,014 50
2020 General $1,330 66
2019 General $3,356 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tayeb Hussain
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Tayeb Hussain were reported at $1,771. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Tayeb Hussain Podiatrist median Middle half National median
2019 $3,356 $196 $72–$601 $163
2020 $1,330 $118 $38–$335 $114
2021 $2,014 $169 $57–$573 $132
2022 $2,951 $220 $74–$782 $149
2023 $1,752 $208 $71–$635 $160
2024 $1,941 $237 $87–$681 $164
2025 $1,771 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,901 159 payments
  2. Smith+Nephew, Inc. $2,563 119 payments
  3. Merete Technologies, Inc $1,500 3 payments
  4. Wright Medical Technology, Inc. $1,155 48 payments
  5. Paragon 28, Inc. $756 14 payments
  6. Treace Medical Concepts, Inc. $403 6 payments
  7. Abbott Laboratories $342 8 payments
  8. Kerecis Limited $285 4 payments
  9. DePuy Synthes Sales Inc. $267 6 payments
  10. Horizon Therapeutics plc $242 9 payments
  11. Other $2,701 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,455 443 payments
  2. Consulting Fee $1,500 3 payments
  3. Travel and Lodging $1,098 3 payments
  4. Education $33 1 payment
  5. Entertainment $29 1 payment
Products named General payments · program years 2019–2025
  1. GRAFIX PL Other Advanced Wound Management $1,608 62 payments
  2. Actishield Biologics $773 24 payments
  3. ACTISHIELD Trauma & Extremities $750 26 payments
  4. VARIAX $638 3 payments
  5. ORTHOLOC 3DI $589 18 payments
  6. AUGMENT INJECTABLE $484 9 payments
  7. VIAFLOW $482 20 payments
  8. Lapiplasty System $373 4 payments
  9. GRAFIX PL Other Advanced Wound Management $351 23 payments
  10. ANCHORAGE $351 15 payments
  11. Other $9,434 291 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$191,081

Of which drugs: $13

Medicare patients

770

Average age 72

Services billed

2,752

409 women, 361 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Arthritis 41%
Diabetes 19%
Ischemic heart disease 18%
Cancer 17%
Depression 17%
Osteoporosis 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 16 $11
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 18 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record